Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AGS-004

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Approaches to deplete persistent HIV infection are needed. We investigated the combined impact of the latency reversing agent… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2018
2018
AGS-004 consists of matured autologous dendritic cells co-electroporated with in vitro transcribed RNA encoding autologous HIV… Expand
  • figure 2
2018
2018
  • Asher Mullard
  • Nature Reviews Drug Discovery
  • 2018
  • Corpus ID: 49470198
the potency and versatility of mRNA to protect against a wide variety of infectious pathogens,” the authors write. The authors… Expand
2018
2018
  • Asher Mullard
  • Nature Reviews Drug Discovery
  • 2018
  • Corpus ID: 49475272
the potency and versatility of mRNA to protect against a wide variety of infectious pathogens,” the authors write. The authors… Expand
2018
2018
  • Asher Mullard
  • Nature Reviews Drug Discovery
  • 2018
  • Corpus ID: 49470418
the potency and versatility of mRNA to protect against a wide variety of infectious pathogens,” the authors write. The authors… Expand
Highly Cited
2016
Highly Cited
2016
Background:The genomic heterogeneity of HIV-1 impedes the ability of consensus sequences in vaccines to elicit effective… Expand
2013
2013
Abstract:We previously reported that a combination of antiretroviral therapy with 4 monthly injections of each patient's own… Expand
2012
2012
Although analytical treatment interruption is used as a strategy to test immunotherapeutic agents in HIV‐infection, it may pose a… Expand
2010
2010
Antiretroviral therapy represents a major breakthrough for the management of HIV-infected patients; however, it is not without… Expand
  • table 1
  • figure 1
Highly Cited
2010
Highly Cited
2010
Immunogenicity, manufacturing feasibility, and safety of a novel, autologous dendritic cell (DC)-based immunotherapy (AGS-004… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2